- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Waltham Today
By the People, for the People
Zenas BioPharma Announces Inducement Grants
Biotech firm grants restricted stock units to new hires under Nasdaq rule
Apr. 20, 2026 at 6:39am
Got story updates? Submit your updates here. ›
Zenas BioPharma's strategic investment in new talent aims to advance its pipeline of transformative autoimmune therapies.Waltham TodayZenas BioPharma, a clinical-stage biopharmaceutical company focused on autoimmune diseases, announced that it has granted an aggregate of 41,475 restricted stock units (RSUs) to newly hired employees as an inducement to join the company, in accordance with Nasdaq Listing Rule 5635(c)(4).
Why it matters
The inducement grants are part of Zenas' strategy to attract top talent to support the development and commercialization of its pipeline of transformative therapies for autoimmune diseases. Offering equity-based compensation is a common practice in the biotech industry to incentivize and retain key employees.
The details
The RSUs will vest over a four-year period, with 25% vesting annually on April 15th from 2027 to 2030. The grants were made under Zenas' 2026 Inducement Plan and are subject to the employees' continued service with the company.
- Zenas granted the RSUs on April 15, 2026.
- The RSUs will vest in four equal installments on April 15, 2027, April 15, 2028, April 15, 2029, and April 15, 2030.
The players
Zenas BioPharma, Inc.
A clinical-stage global biopharmaceutical company committed to developing transformative therapies for patients living with autoimmune diseases.
Nasdaq Listing Rule 5635(c)(4)
A Nasdaq rule that allows companies to grant equity-based compensation as an inducement to new hires without shareholder approval.
The takeaway
Zenas' inducement grants demonstrate the company's commitment to building a talented team to advance its pipeline of autoimmune disease therapies. Offering equity-based compensation is a common strategy in the biotech industry to attract and retain top scientific and clinical talent.
